Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GW869682 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| GW869682 1000 mg thrice daily (TID) | EXPERIMENTAL | Subjects will be randomized to receive GW869682 1000 mg TID |
| GSK189075 250 mg TID | EXPERIMENTAL | Subjects will be randomized to receive GSK189075 250 mg TID |
| GW869682-Placebo TID | PLACEBO_COMPARATOR | Subjects will be randomized to receive Placebo matching GW869682 for TID |
| GSK189075-Placebo TID | PLACEBO_COMPARATOR | Subjects will be randomized to receive Placebo matching GSK189075 for TID |
| Name | Type | Description |
|---|---|---|
| GW869682 | DRUG | - |
| GSK189075 | DRUG | GSK189075 tablet with a dose strength of 250 mg will be available for subjects |
| GSK189075-Placebo | DRUG | Placebo tablets to match GSK189075 250 mg will be available for subjects |
| GW869682-Placebo | DRUG | Placebo tablets to match GW869682 250 mg will be available for subjects |
Inclusion criteria: * Have a BMI within range 30.0 to 40.0kg/m2, inclusive. * Females who meet above criteria must be physiologically incapable of becoming pregnant (ie., surgically sterilized, or post-menopausal per protocol definition). Exclusion criteria: * History of eating disorders. * Recen...
Top 20 of 32 competitors
GW869682 is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus and Obesity. It is being developed by GSK plc (GSK) and is currently in Phase 1 clinical development. The drug has been evaluated in clinical trials for weight loss in obese subjects and for weight loss and body composition changes in patients with Type 2 Diabetes and Obesity.
GW869682 is being developed by GSK plc, a global pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is an investigational small molecule in Phase 1 clinical development for metabolic conditions including Type 2 Diabetes Mellitus and Obesity.
GW869682 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug has completed clinical trials, including a Phase 2 study for obesity and a Phase 1 study for Type 2 Diabetes Mellitus and Obesity, but it remains in early-stage development.
GW869682 has been studied in two completed clinical trials. NCT00297180 was a Phase 2 study of weight loss in 136 obese subjects taking GW869682 or placebo three times daily for 12 weeks in the United States. NCT00494767 was a Phase 1 study of weight loss and body composition changes in 27 subjects with Type 2 Diabetes and Obesity in the United Kingdom.
GW869682 is a unique investigational compound and no alternative names have been reported. It is a small molecule being developed by GSK plc for metabolic conditions. The drug is distinct from other agents and is identified by its code name GW869682 in clinical trial registries.